Abstract:In this study, the natural molecular history of matched primary and recurrent tumors of 19 patients with IDH‐mutant, 1p19q non‐codeleted astrocytomas without pressure of temozolomide or radiotherapy was studied. Samples were examined for DNA methylation profiling and copy number variations, gene mutations and ALT. Recurrences were characterized by new CNVs not present in the primary tumors. Few novel mutations were identified in recurrences. CDKN2A homozygous deletion, MYC or PDGFRA focal and non‐focal gain were found at recurrences. Our findings improve the understanding of the molecular life history of IDH‐mutant astrocytomas. Hypermutation and malignant transformation are potential complications arising from temozolomide treatment of IDH‐mutant gliomas. However, the natural history of IDH‐mutant low‐grade gliomas without temozolomide treatment is actually under‐studied. We retrieved retrospectively from our hospitals paired tumors from 19 patients with IDH‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas where no interim adjuvant treatment with either temozolomide or radiotherapy was given between primary resections and first recurrences. Tissues from multiple recurrences were available from two patients and radiotherapy but not temozolomide was given before the last specimens were resected. We studied the natural molecular history of these low‐grade IDH‐mutant astrocytomas without pressure of temozolomide with DNA methylation profiling and copy number variation (CNV) analyses, targeted DNA sequencing, TERTp sequencing, FISH for ALT and selected biomarkers. Recurrences were mostly higher grades (15/19 patients) and characterized by new CNVs not present in the primary tumors (17/19 cases). Few novel mutations were identified in recurrences. Tumors from 17/19 (89.5%) patients showed either CDKN2A homozygous deletion, MYC or PDGFRA focal and non‐focal gains at recurrences. There was no case of hypermutation. Phylogenetic trees constructed for tumors for the two patients with multiple recurrences suggested a lack of subclone development in their evolution when under no pressure from temozolomide. In summary, our studies demonstrated, in contrast to the phenomenon of temozolomide‐induced hypermutation, IDH‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas which had not been treated by temozolomide, acquired new CNVs at tumor recurrences. These findings improve our understanding of the molecular life history of IDH‐mutant astrocytomas.

Genetic And Epigenetic Features Of Rapidly Progressing Idh-Mutant Astrocytomas

Exth-30. Genetic Alterations That Deregulate Rb And Pdgfra Signaling Pathways Drive Tumor Progression In Idh2-Mutant Astrocytoma

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma

Molecular Signatures of Chromosomal Instability Correlate with Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas.

Global DNA Methylation Profiling Reveals Chromosomal Instability in IDH-mutant Astrocytomas

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma

Total Copy Number Variation As a Prognostic Factor in Adult Astrocytoma Subtypes

Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes

IDH Mutant Lower Grade (WHO Grades II/III) Astrocytomas Can Be Stratified for Risk by CDKN2A, CDK4 and PDGFRA Copy Number Alterations.

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database

Epco-26. Longitudinal Single-Cell Analyses Identify Drivers Of Genetic, Epigenomic, And Cellular Evolution In Idh-Mutant Glioma

The molecular history of IDH‐mutant astrocytomas without adjuvant treatment

Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis

Epco-31. The Germline Polymorphism Rs55705857 Is Associated With A Poor Survival In Astrocytoma, Idh-Mutant, Grade 2

Path-44. Clinical And Radiographic Predictors Of Prognosis In Astrocytoma, Idh-Mutant, Who Grade 4

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

Path-29. Longitudinal Epigenomic Evolution Of Idh-Wildtype Glioblastoma

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

IDH-mutant gliomas with additional class-defining molecular events

IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma